NCT03776539 - A Study to Evaluate the Effects of Renal Impairment on the Pharmacokinetics of ELX-02 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 4, 2019

Primary Completion Date

July 30, 2019

Study Completion Date

August 7, 2019

Conditions

Impaired Renal Function

Interventions

DRUG

ELX-02

ELX-02 is a synthetic, designer eukaryotic ribosomal specific glycoside (ERSG) optimized as a translational read-through drug. All groups will get the same treatment.

Trial Locations (2)

33136

Inventiv Health Clinical -Research Pharmacy Unit, Miami

University of Miami, Miami